Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Neurogene Inc. - Common Stock (NQ: NGNE ) 40.27 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Neurogene Inc. - Common Stock NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024 August 09, 2024 NGNE stock results show that Neurogene missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates August 09, 2024 From Neurogene Inc. Via Business Wire Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome August 07, 2024 From Neurogene Inc. Via Business Wire Neurogene to Participate in BMO Genetic Medicines Summit July 02, 2024 From Neurogene Inc. Via Business Wire MicroMarvel Neurogene Challenges Big Pharma January 22, 2024 Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Via Talk Markets Neurogene Announces Addition to Russell 3000® Index July 01, 2024 From Neurogene Inc. Via Business Wire 12 Health Care Stocks Moving In Thursday's Pre-Market Session June 20, 2024 Via Benzinga Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session June 18, 2024 Via Benzinga Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome June 18, 2024 From Neurogene Inc. Via Business Wire Neurogene to Participate in Upcoming Conferences June 05, 2024 From Neurogene Inc. Via Business Wire Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program June 03, 2024 From Neurogene Inc. Via Business Wire NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024 May 10, 2024 NGNE stock results show that Neurogene beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates May 10, 2024 From Neurogene Inc. Via Business Wire Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting May 07, 2024 From Neurogene Inc. Via Business Wire Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting April 22, 2024 From Neurogene Inc. Via Business Wire 7 A-Rated Aggressive Biotech Stocks to Bet On in 2024 April 12, 2024 We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades. Via InvestorPlace Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates March 18, 2024 From Neurogene Inc. Via Business Wire Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial March 04, 2024 From Neurogene Inc. Via Business Wire Neurogene to Participate in Upcoming Investor Conferences February 29, 2024 From Neurogene Inc. Via Business Wire Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer January 16, 2024 From Neurogene Inc. Via Business Wire Neurogene Announces Business Update and 2024 Outlook January 05, 2024 From Neurogene Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.